Cargando…

Somatopause, weaknesses of the therapeutic approaches and the cautious optimism based on experimental ageing studies with soy isoflavones

The pathological phenomenon of somatopause, noticeable in hypogonadal ageing subjects, is based on the growth hormone (GH) production and secretion decrease along with the fall in GH binding protein and insulin-like growth factor 1 (IGF-1) levels, causing different musculoskeletal, metabolic and men...

Descripción completa

Detalles Bibliográficos
Autores principales: Ajdžanovic, Vladimir Z., Trifunovic, Svetlana, Miljic, Dragana, Šošic-Jurjevic, Branka, Filipovic, Branko, Miler, Marko, Ristic, Nataša, Manojlovic-Stojanoski, Milica, Miloševic, Verica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Leibniz Research Centre for Working Environment and Human Factors 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938552/
https://www.ncbi.nlm.nih.gov/pubmed/29743865
http://dx.doi.org/10.17179/excli2017-956
_version_ 1783320805956911104
author Ajdžanovic, Vladimir Z.
Trifunovic, Svetlana
Miljic, Dragana
Šošic-Jurjevic, Branka
Filipovic, Branko
Miler, Marko
Ristic, Nataša
Manojlovic-Stojanoski, Milica
Miloševic, Verica
author_facet Ajdžanovic, Vladimir Z.
Trifunovic, Svetlana
Miljic, Dragana
Šošic-Jurjevic, Branka
Filipovic, Branko
Miler, Marko
Ristic, Nataša
Manojlovic-Stojanoski, Milica
Miloševic, Verica
author_sort Ajdžanovic, Vladimir Z.
collection PubMed
description The pathological phenomenon of somatopause, noticeable in hypogonadal ageing subjects, is based on the growth hormone (GH) production and secretion decrease along with the fall in GH binding protein and insulin-like growth factor 1 (IGF-1) levels, causing different musculoskeletal, metabolic and mental issues. From the perspective of safety and efficacy, GH treatment is considered to be highly controversial, while some other therapeutic approaches (application of IGF-1, GH secretagogues, gonadal steroids, cholinesterase-inhibitors or various combinations) exhibit more or less pronounced weaknesses in this respect. Soy isoflavones, phytochemicals that have already demonstrated the health benefits in treated elderly, at least experimentally reveal their potential for the somatopausal symptoms remediation. Namely, genistein enhanced GHRH-stimulated cAMP accumulation and GH release in rat anterior pituitary cells; refreshed and stimulated the somatotropic system (hypothalamic nuclei and pituitary GH cells) function in a rat model of the mild andropause, and stimulated the GH output in ovariectomized ewes as well as the amplitude of GH pulses in the rams. Daidzein, on the other hand, increased body mass, trabecular bone mass and decreased bone turnover in the animal model of severe andropause, while both isoflavones demonstrated blood cholesterol-lowering effect in the same model. These data, which necessarily need to be preclinically and clinically filtered, hint some cautious optimism and call for further innovative designing of balanced soy isoflavone-based therapeutics.
format Online
Article
Text
id pubmed-5938552
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Leibniz Research Centre for Working Environment and Human Factors
record_format MEDLINE/PubMed
spelling pubmed-59385522018-05-09 Somatopause, weaknesses of the therapeutic approaches and the cautious optimism based on experimental ageing studies with soy isoflavones Ajdžanovic, Vladimir Z. Trifunovic, Svetlana Miljic, Dragana Šošic-Jurjevic, Branka Filipovic, Branko Miler, Marko Ristic, Nataša Manojlovic-Stojanoski, Milica Miloševic, Verica EXCLI J Review Article The pathological phenomenon of somatopause, noticeable in hypogonadal ageing subjects, is based on the growth hormone (GH) production and secretion decrease along with the fall in GH binding protein and insulin-like growth factor 1 (IGF-1) levels, causing different musculoskeletal, metabolic and mental issues. From the perspective of safety and efficacy, GH treatment is considered to be highly controversial, while some other therapeutic approaches (application of IGF-1, GH secretagogues, gonadal steroids, cholinesterase-inhibitors or various combinations) exhibit more or less pronounced weaknesses in this respect. Soy isoflavones, phytochemicals that have already demonstrated the health benefits in treated elderly, at least experimentally reveal their potential for the somatopausal symptoms remediation. Namely, genistein enhanced GHRH-stimulated cAMP accumulation and GH release in rat anterior pituitary cells; refreshed and stimulated the somatotropic system (hypothalamic nuclei and pituitary GH cells) function in a rat model of the mild andropause, and stimulated the GH output in ovariectomized ewes as well as the amplitude of GH pulses in the rams. Daidzein, on the other hand, increased body mass, trabecular bone mass and decreased bone turnover in the animal model of severe andropause, while both isoflavones demonstrated blood cholesterol-lowering effect in the same model. These data, which necessarily need to be preclinically and clinically filtered, hint some cautious optimism and call for further innovative designing of balanced soy isoflavone-based therapeutics. Leibniz Research Centre for Working Environment and Human Factors 2018-03-21 /pmc/articles/PMC5938552/ /pubmed/29743865 http://dx.doi.org/10.17179/excli2017-956 Text en Copyright © 2018 Ajdžanovic et al. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (http://creativecommons.org/licenses/by/4.0/) You are free to copy, distribute and transmit the work, provided the original author and source are credited.
spellingShingle Review Article
Ajdžanovic, Vladimir Z.
Trifunovic, Svetlana
Miljic, Dragana
Šošic-Jurjevic, Branka
Filipovic, Branko
Miler, Marko
Ristic, Nataša
Manojlovic-Stojanoski, Milica
Miloševic, Verica
Somatopause, weaknesses of the therapeutic approaches and the cautious optimism based on experimental ageing studies with soy isoflavones
title Somatopause, weaknesses of the therapeutic approaches and the cautious optimism based on experimental ageing studies with soy isoflavones
title_full Somatopause, weaknesses of the therapeutic approaches and the cautious optimism based on experimental ageing studies with soy isoflavones
title_fullStr Somatopause, weaknesses of the therapeutic approaches and the cautious optimism based on experimental ageing studies with soy isoflavones
title_full_unstemmed Somatopause, weaknesses of the therapeutic approaches and the cautious optimism based on experimental ageing studies with soy isoflavones
title_short Somatopause, weaknesses of the therapeutic approaches and the cautious optimism based on experimental ageing studies with soy isoflavones
title_sort somatopause, weaknesses of the therapeutic approaches and the cautious optimism based on experimental ageing studies with soy isoflavones
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938552/
https://www.ncbi.nlm.nih.gov/pubmed/29743865
http://dx.doi.org/10.17179/excli2017-956
work_keys_str_mv AT ajdzanovicvladimirz somatopauseweaknessesofthetherapeuticapproachesandthecautiousoptimismbasedonexperimentalageingstudieswithsoyisoflavones
AT trifunovicsvetlana somatopauseweaknessesofthetherapeuticapproachesandthecautiousoptimismbasedonexperimentalageingstudieswithsoyisoflavones
AT miljicdragana somatopauseweaknessesofthetherapeuticapproachesandthecautiousoptimismbasedonexperimentalageingstudieswithsoyisoflavones
AT sosicjurjevicbranka somatopauseweaknessesofthetherapeuticapproachesandthecautiousoptimismbasedonexperimentalageingstudieswithsoyisoflavones
AT filipovicbranko somatopauseweaknessesofthetherapeuticapproachesandthecautiousoptimismbasedonexperimentalageingstudieswithsoyisoflavones
AT milermarko somatopauseweaknessesofthetherapeuticapproachesandthecautiousoptimismbasedonexperimentalageingstudieswithsoyisoflavones
AT risticnatasa somatopauseweaknessesofthetherapeuticapproachesandthecautiousoptimismbasedonexperimentalageingstudieswithsoyisoflavones
AT manojlovicstojanoskimilica somatopauseweaknessesofthetherapeuticapproachesandthecautiousoptimismbasedonexperimentalageingstudieswithsoyisoflavones
AT milosevicverica somatopauseweaknessesofthetherapeuticapproachesandthecautiousoptimismbasedonexperimentalageingstudieswithsoyisoflavones